drugset / Trial / NCT04750057
Anifrolumab Early Access Program
Summary
To provide early access (ie, before marketing authorisation) to anifrolumab 300 mg IV Q4W while receiving standard therapy in adult patients with moderate-to-severe active SLE
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anifrolumab | Monoclonal antibody | 300 mg | Intravenous |